5.35
price up icon1.52%   0.08
after-market 시간 외 거래: 5.39 0.04 +0.75%
loading
전일 마감가:
$5.27
열려 있는:
$5.275
하루 거래량:
522.70K
Relative Volume:
0.24
시가총액:
$293.98M
수익:
$3.64M
순이익/손실:
$-87.37M
주가수익비율:
-1.3017
EPS:
-4.11
순현금흐름:
$-86.46M
1주 성능:
+1.90%
1개월 성능:
+15.80%
6개월 성능:
-4.29%
1년 성능:
+49.03%
1일 변동 폭
Value
$5.265
$5.40
1주일 범위
Value
$4.86
$5.57
52주 변동 폭
Value
$2.10
$9.10

Verastem Inc Stock (VSTM) Company Profile

Name
명칭
Verastem Inc
Name
전화
(781) 292-4200
Name
주소
117 KENDRICK STREET, NEEDHAM, MA
Name
직원
78
Name
트위터
@VerastemOncolog
Name
다음 수익 날짜
2024-11-06
Name
최신 SEC 제출 서류
Name
VSTM's Discussions on Twitter

VSTM을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
VSTM
Verastem Inc
5.35 289.58M 3.64M -87.37M -86.46M -4.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Verastem Inc Stock (VSTM) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-10 개시 Jefferies Buy
2025-03-24 재확인 H.C. Wainwright Buy
2024-12-31 재확인 BTIG Research Buy
2024-09-30 개시 Guggenheim Buy
2023-11-21 재개 BTIG Research Buy
2023-09-27 개시 B. Riley Securities Buy
2023-06-15 업그레이드 Mizuho Neutral → Buy
2022-09-07 재개 Alliance Global Partners Buy
2022-04-29 재개 Cantor Fitzgerald Overweight
2022-04-14 개시 RBC Capital Mkts Outperform
2022-03-09 개시 Truist Buy
2021-07-01 개시 Alliance Global Partners Buy
2021-05-24 업그레이드 BTIG Research Neutral → Buy
2019-06-20 다운그레이드 BTIG Research Buy → Neutral
2019-05-10 다운그레이드 Raymond James Outperform → Mkt Perform
2018-07-13 개시 BTIG Research Buy
2018-05-02 개시 Seaport Global Securities Buy
2018-03-08 개시 B. Riley FBR, Inc. Buy
2017-09-07 재확인 H.C. Wainwright Buy
2017-04-13 개시 Oppenheimer Outperform
2017-03-24 재확인 H.C. Wainwright Buy
2015-09-29 다운그레이드 Cantor Fitzgerald Buy → Hold
2015-09-29 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2015-09-29 다운그레이드 Jefferies Buy → Hold
2015-09-29 다운그레이드 Raymond James Strong Buy → Outperform
2015-09-28 다운그레이드 Mizuho Buy → Neutral
2015-09-28 다운그레이드 ROTH Capital Buy → Neutral
2015-09-09 개시 Raymond James Strong Buy
2015-05-12 재확인 UBS Buy
2015-04-08 개시 H.C. Wainwright Buy
2015-01-23 재확인 ROTH Capital Buy
2014-07-08 재개 Oppenheimer Perform
2014-02-11 개시 Mizuho Buy
모두보기

Verastem Inc 주식(VSTM)의 최신 뉴스

pulisher
Jul 23, 2025

Published on: 2025-07-24 00:31:57 - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Is Verastem Inc. a good long term investmentConsistent high-yield stocks - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - The Malaysian Reserve

Jul 23, 2025
pulisher
Jul 23, 2025

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - Benzinga

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Verastem Inc. stockFree Expert Stock Watchlist - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Verastem Inc. stock priceUnmatched profit potential - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Verastem Inc. Stock Analysis and ForecastMarket-beating returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

(VSTM) Proactive Strategies - news.stocktradersdaily.com

Jul 22, 2025
pulisher
Jul 18, 2025

Verastem’s Promising KRAS G12D Inhibitor Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 16, 2025

Verastem: The Market Is Ignoring The Progress (NASDAQ:VSTM) - Seeking Alpha

Jul 16, 2025
pulisher
Jul 16, 2025

Why Verastem Inc. stock attracts strong analyst attentionDaily Trade Opportunity - beatles.ru

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Verastem Inc. stock price move sharplyEntry Level Low Risk Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Verastem Inc. stock performs during market volatilityFast Moving Stock Alerts - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Avutometinib-Defactinib: A New Standard in Precision Oncology? - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Verastem’s avutometinib combination shows 31% ORR in ovarian cancer trial - Yahoo Finance

Jul 14, 2025
pulisher
Jul 11, 2025

Verastem Oncology's Breakthrough in LGSOC: A New Standard of Care with Substantial Upside Potential - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Verastem’s cancer drug shows 31% response rate in ovarian cancer trial By Investing.com - Investing.com Canada

Jul 11, 2025
pulisher
Jul 11, 2025

Verastem stock rises after LGSOC treatment data published in medical journal - Investing.com

Jul 11, 2025
pulisher
Jul 11, 2025

Verastem stock rises after LGSOC treatment data published in medical journal By Investing.com - Investing.com South Africa

Jul 11, 2025
pulisher
Jul 11, 2025

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology - Yahoo Finance

Jul 11, 2025
pulisher
Jul 10, 2025

KRAS Inhibitors Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Target Population, Revenue, Statistics, MOA, ROA and Companies DelveInsight - Barchart.com

Jul 10, 2025
pulisher
Jul 08, 2025

Verastem Oncology's Talent Incentives: Balancing Equity Dilution and Growth - AInvest

Jul 08, 2025
pulisher
Jul 08, 2025

Verastem Oncology announces inducement grants under Nasdaq listing rule - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Verastem Oncology Awards 45,000 Share Options at $4.29 Each to Expand Cancer Drug Development Team - Stock Titan

Jul 08, 2025
pulisher
Jul 04, 2025

Verastem’s Phase 3 Study on Avutometinib and Defactinib: A Potential Game-Changer for Ovarian Cancer Treatment - TipRanks

Jul 04, 2025
pulisher
Jul 02, 2025

Verastem’s Promising Phase 3 Study on Recurrent Ovarian Cancer - TipRanks

Jul 02, 2025
pulisher
Jul 01, 2025

How the (VSTM) price action is used to our Advantage - news.stocktradersdaily.com

Jul 01, 2025
pulisher
Jun 30, 2025

Verastem’s Promising Phase 3 Study on Avutometinib and Defactinib in Ovarian Cancer - TipRanks

Jun 30, 2025
pulisher
Jun 28, 2025

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

Jun 28, 2025
pulisher
Jun 26, 2025

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers - Seeking Alpha

Jun 26, 2025
pulisher
Jun 25, 2025

Verastem (VSTM) Target Price Lowered by RBC Capital | VSTM Stock News - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

RBC Capital Adjusts Target Price for Verastem (VSTM) to $12 | VS - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

RBC Capital Adjusts Target Price for Verastem (VSTM) to $12 | VSTM Stock News - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors - BioSpace

Jun 25, 2025
pulisher
Jun 24, 2025

Verastem Executives Sell Shares to Meet Tax Obligations - TradingView

Jun 24, 2025

Verastem Inc (VSTM) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
자본화:     |  볼륨(24시간):